Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 10
Submit an article Journal homepage
320
Views
2
CrossRef citations to date
0
Altmetric
Review

Management of narcolepsy

Abid Bhat Hospital Hill, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Truman Medical Center, Kansas City, MO, USA; University of Missouri at Kansas City, MO, USA
, MD &
Ali A El Solh State University of New York at Buffalo, Western New York Respiratory Research Center, Department of Medicine, Buffalo, NY, USA; Erie County Medical Center, Critical Care, and Sleep Medicine, Division of Pulmonary, 462 Grider Street, Buffalo, NY 14215, USA +1 716 898 3375; +1 716 898 6139; [email protected]
, MD MPH
Pages 1721-1733 | Published online: 21 Jun 2008

Bibliography

  • Westphal C. Eigentumliche mit Einschlafen verbundene Anfalle. Arch Psychiatr Nervenkr 1877;7:631-5
  • Gelineau J. De la narcolepsie. Gaz Hop 1880;53:626-8
  • Abad V, Guilleminault C. Emerging drugs for narcolepsy. Expert Opin Emerging Drugs 2004;9:281-9
  • Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs 2007;21:337-54
  • Broughton R, Dunham W, Newman J, et al. Ambulatory 24 hour sleep–wake monitoring in narcolepsy–cataplexy compared to matched controls. Electroencephalogr. Clin Neurophysiol 1988;70:473-81
  • Dantz B, Edgar D, Dement WC. Circadian rhythm in narcolepsy: studies on a 90 minute day. Electroencephalogr. Clin Neurophysiol 1994;90:24-35
  • Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. Adv Neurol 1995;67:65-77
  • Anic-Labat S, Guilleminault C, Kraemer H, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87
  • Hublin C, Partinen M, Kaprio J, et al. Epidemiology of narcolepsy. Sleep 1994;17:S7-12
  • Honda Y. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa city. Sleep Res 1979;8:191
  • Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep 1987;10:608-9
  • Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001;2:5-17
  • Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57:2029-33
  • Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62
  • Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91
  • Dalal M, Schuld A, Haack M, et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 2001;56:1749-51
  • Thannickal T. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
  • Crocker A, Espana R, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65:1184-8
  • Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50:S16-22
  • Overeem S, Black J III, Lammers GJ. Narcolepsy: immunological aspects. Sleep Med Rev 2008;12:95-107
  • Icsd-2. editor. ICSD-2 International classification of sleep disorders, diagnostic and coding manual. 2nd edition. Westchester, IL: American Academy of Sleep Medicine; 2005
  • Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4:57-99
  • Browman C, Gujavarty K, Mitler M. Tobacco use by narcoleptics and daytime sleep tendency. Drug Alcohol Depend 1984;14:23-6
  • Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy–cataplexy. Sleep 1993;16:444-56
  • Rogers A, Aldrich M, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001;24:385-91
  • Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology 1998;50:S31
  • Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine, methylphenidate and modafinil induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996;93:14128-33
  • Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992;591:319-26
  • Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:436-37
  • Gallopin T, Luppi P, Rambert FA, et al. Effect of the wake promoting agent modafinil on sleep promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004;27:19-25
  • Saper C, Scammell TE. Modafinil: a drug in search of a mechanism. Sleep 2004;27:11-2
  • Wisor JP, Eriksson KS. Dopaminergic–adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005;132:1027-34
  • Scammell T, Estabrooke I, Mccarthy MT, et al. Hypothalamic arousal regions are activated during modafinil induced wakefulness. J Neurosci 2000;20:8620-8
  • Ferraro L, Tanganellis S, O'Connor W, et al. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 1996;220:5-8
  • Wise M, Arand D, Auger R, et al. Treatment of narcolepsy and other hypersomnias of central origin. An American Academy of Sleep Medicine Review. Sleep 2007;30:1712-27
  • US Modafinil in Narcolepsy Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
  • U.S. Modafinil in Narcolepsy Study Group: Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75
  • Mitler M, Harsch J, Hirshkowitz M, et al. Long-term efficacy and safety of modafinil for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep 1994;17:352-71
  • Schwartz J, Feldman N, Bogan RK. Dose response and dose regimen effects of modafinil in sustaining daytime wakefulness in narcolepsy patients with residual excessive sleepiness. J Neuropsychiatry Clin Neurosci 2005;17(3):405-12
  • Moldofsky H, Broughton RJ, Hill JD, et al. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1:109-16
  • Becker P, Schwartz J, Feldman N, et al. Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology 2004;171:133-9
  • Thorpy M, Schwartz J, Kovacevic-Ristanovic R, et al. Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label study assessing three strategies. Psychopharmacology 2003;167:380-5
  • Guilleminault C, Aftab F, Karadeniz D, et al. Problems associated with switch to modafinil – a novel alerting agent in narcolepsy. Eur J Neurol 2000;7:381-4
  • Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo controlled, ascending dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999;39:30
  • Smith DE, Calhoun SR, Galloway GP, et al. Postmarketing surveillance of modafinil abuse and misuse. Sleep 2004;27(Suppl):A57
  • Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003;4:579-82
  • Wisor JP, Dement WC, Aimone L, et al. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006;85:492-9
  • Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74
  • Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22:159-76
  • Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA 1935;105:2051-4
  • Mitler MM, Aldrich MS, Koob GF, et al. Narcolepsy and its treatment with stimulants. Sleep 1994;17:352-71
  • Sulzer D. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005;75(6):406-33
  • Daly D. Yoss R. The treatment of narcolepsy with methyl phenylpiperidylacetate. A preliminary report. Staff Meet Mayo Clin 1956;31:620-25
  • Mitler MM, Shafor R, Hajdukovich R, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986;9:260-4
  • Schindler J, Schacter M, Brincat S, et al. Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 1985;290:1167-70
  • Mitler MM, Hajdukovic R, Erman M. Narcolepsy. J Clin Neurophysiol 1990;7:93-118
  • Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep 1993;16:306-17
  • Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13:1035-48
  • Guilleminault C. Amphetamines and narcolepsy: use of the Stanford database. Sleep 1993;16:199-201
  • Wallin MT, Mahowald MW. Blood pressure effects of long-term stimulant use in disorders of hypersomnolence. J Sleep Res 1998;7:209-15
  • Auger RR, Goodmann SH, Silber MH, et al. Risks of high dose stimulants in the treatment of disorders of excessive somnolence. A case control study. Sleep 2005;28:667-72
  • Bassetti C, Aldrich MS. Narcolepsy. Neurol Clin 1996;14(3):545-71
  • Mayer G, Ewert-Meier K, Hephata K. Selegiline hydrochloride treatment in narcolepsy: a double-blind, placebo controlled study. Clin Neuropharmacol 1995;18:306-19
  • Reinish LW, Macfarlane JG, Sandor P, et al. REM changes in narcolepsy with selegiline. Sleep 1995;18(5):362-7
  • Honda Y, Hishikawa Y. A long-term treatment of narcolepsy and excessive daytime sleepiness with pemoline. Curr Ther Res 1980;9:265-8
  • Iijima S, Sugita Y, Teshima Y, et al. Therapeutic efficacy of mazindol on narcolepsy. Sleep 1986;9:265-8
  • Parkes JD, Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand 1979;60:250-4
  • Vespignani H, Barroche G, Escaillas JP, et al. Importance of mazindol in the treatment of narcolepsy. Sleep 1984;7:274-5
  • Thorpy MJ. Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. CNS Drugs 2006;20(1):43-50
  • Szabo ST, Gold MS, Goldberger BA, et al. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus ceruleus norepinephrine neurons. Biol Pschiatry 2004;55(9):934-9
  • Madden TE, Johnson SW. Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 1998;287:262-5
  • Carter LP, Wu H, Chen W, et al. Effects of γ-hydroxybutyrate (GHB) on scheduled controlled responding in rats: role of GHB and GABAB receptors. J Pharmacol Exp Ther 2004;308:182-6
  • Carter LP, Wu H, Chen W, et al. Novel γ-hydroxybutyric acid (GHB) analogs share some, but not all, of the behavioral effects of GHB and GABAB receptor agonists. J Pharmacol Exp Ther 2005;313(3):1314-23
  • Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997;100:745-53
  • Mamelak M, Black J, Montplaisir J, et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004;27(7):1327-34
  • Bedard MA, Montplaisir J, Godbout R, et al. Nocturnal γ-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989;12(1):29-36
  • Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy/cataplexy. Can J Neurol Sci 1980;7(1):23-31
  • Lapierre O, Montplaisir J, Lamarre M, et al. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep 1990;13(1):24-30
  • Lankford A. Sodium oxybate significantly improves sleep architecture in patients with narcolepsy. In: New research abstracts. American Psychiatric Association 2005 Annual Meeting; 2005. p. 202-3
  • US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26(1):31-5
  • The Xyrem International Study Group. A double-blind placebo controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-7
  • Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29:939-46
  • US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9
  • Fuller DE, Hornfeldt C, Kelloway JS, et al. The Xyrem Risk Management Program. Drug Saf 2004;27(50):293-306
  • Tunnicliffe G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol 1992;23:1027-34
  • US Xyrem Multicenter Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21
  • US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23
  • Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:1-3
  • Hishikawa Y, Ida H, Nakai K, et al. Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran). J Neurol Sci 1966;3:453-61
  • Guilleminault C, Wilson R, Dement WC. A study on cataplexy. Arch Neurol 1974;31:255-61
  • Chen CN. The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad. Med J 1980;56(Suppl 1):86-9
  • Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol 1975;32:653-6
  • Guilleminault C, Raynal D, Takahashi S, et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976;54:71-87
  • Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17:113-6
  • Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994;44:707-9
  • Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78
  • Langdon N, Shindler J, Parkes JD, et al. Fluoxetine in the treatment of cataplexy. Sleep 1986;9:371-3
  • Poryazova R, Siccoli M, Werth E. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005;65:967-8
  • Smith M, Parkes JD, Dahlitz M: Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996;5(Suppl 1):217
  • Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy. Rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992;32:3-10
  • Fujiki N, Yoshida Y, Ripley B, et al. Effects of IV and ICV hypocretin-1 orexin A in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003;26:953-9
  • Arias-Carrión O, Murillo-Rodriguez E, Xu M, et al. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004;27:1465-70
  • Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12:347-8
  • Dauvilliers Y, Carlander B, Touchon J, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56:905-8
  • Zuberi S, Mignot E, Ling L, et al. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res 2004;13(Suppl 1):828
  • Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007;254:1607-8
  • Zeman A, Britton T, Douglas N, et al. Narcolepsy and excessive daytime sleepiness. BMJ 2004;329:724-8
  • Mignot E, Hhayduk R, Black J, et al. HLA DQBI*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-20
  • Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007;8:373-99
  • Lin L, Fraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76
  • Chemelli R, Willie J, Sinton TM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51
  • Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8
  • Morgenthaler T, Kapur V, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-11

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.